A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis

Exclusion Criteria

• •1. Women who are pregnant or breastfeeding.
• •2. Positive test result for Hepatitis B surface antigen (HBsAg) or positive human immunodeficiency virus (HIV) antibody (confirmed by Western Blot).
• •3. Any current or past clinical evidence of Child-Pugh B or C classification or clinical history of liver decompensation such as ascites (noted on physical exam), variceal bleeding, or hepatic encephalopathy.
• •4. Confirmed presence of hepatocellular carcinoma indicated on imaging techniques such as computed tomography (CT) scan or magnetic resonance imaging (MRI) within 3 months prior to Screening or on an ultrasound performed at Screening (a positive ultrasound result will be confirmed with CT scan or MRI.)
• •5. Use of contraindicated medications within 2 weeks of dosing
• •6. Screening laboratory analyses showing any of the following abnormal laboratory results:
• •* Calculated creatinine clearance (using Cockcroft-Gault method) \< 30 mL/min
• •* Albumin \< 2.8 g/dL
• •* International normalized ratio (INR) \> 1.8. Participants with a known inherited blood disorder and INR \> 1.8 may be enrolled with permission of the AbbVie Study Designated Physician.
• •* Hemoglobin \< 10 g/dL
• •* Platelets \< 25,000 cells per mm3
• •* Total bilirubin \> 3.0 mg/dL